Have a personal or library account? Click to login
Therapeutic Drug Monitoring of Venlafaxine and Impact of Age, Gender, BMI, and Diagnosis Cover

Therapeutic Drug Monitoring of Venlafaxine and Impact of Age, Gender, BMI, and Diagnosis

Open Access
|Nov 2020

References

  1. Alventa SPC. (https://www.adc.sk/databazy/produkty/spc/alventa-75-mg-304880.html). Revised October 2019. Accessed December 20, 2019.
  2. American Psychiatric Association (APA). DSM-5. (https://www.psychiatry.org/psychiatrists/practice/dsm). Revised October 2018. Accessed January 24, 2020.
  3. Cai L, Xu L, Wei L, Chen W. Relationship of Mean Platelet Volume To MDD: A Retrospective Study. Shanghai Arch Psychiatry. 2017;29(1):21–29.
  4. Hansen MR, Kuhlmann IB, Pottegård A, Damkier P. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships. Basic Clin Pharmacol Toxicol. 2017;121(4):298–302.
  5. Hiemke C. Clinical utility of drug measurements and pharmacokinetics – therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol. 2008;64:159–166.
  6. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62.
  7. Kertys M, Krivosova M, Ondrejka I, Hrtanek I, Tonhajzerova I, Mokry J. Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC–MS/MS using one-step sample preparation procedure. J Pharm Biomed Anal. 2020;181:113098.
  8. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62(4):321–6.
  9. Luppa M, Sikorski C, Luck T, et al. Age- and gender-specific prevalence of depression in latest-life--systematic review and meta-analysis. J Affect Disord. 2012;136(3):212–21.
  10. Marazziti D, Baroni S, Picchetti M, et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr. 2013;18(3):118–27.
  11. National health information center (NHIC). Prescription Drug Use in Slovak Republic in 2018. (http://www.nczisk.sk/Statisticke_vystupy/Tematicke_statisticke_vystupy/TOP-50-liekov/Pages/Spotreba-humannych-liekov-v-slovenskej-republike.aspx). Revised December 2019. Accessed January 24, 2020.
  12. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41(2):149–56.
  13. Paulzen M, Groppe S, Tauber SC, Veselinovic T, Hiemke C, Gründer G. Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. J Clin Psychiatry. 2015;76(1):25–31.
  14. Reis M, Aamo T, Spigset O, Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31(1):42–56.
  15. Reyes-Barron C, Tonarelli S, Delozier A, et al. Pharmacogenetics of antidepressants, a review of significant genetic variants in different populations. Clin. Depress. 2016;2(1):109.
  16. Sigurdsson HP, Hefner G, Ben-omar N, et al. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. J Neural Transm (Vienna). 2015;122(5):721–9.
  17. State Institute for Drug Control (SIDC). Database of medicaments. (https://www.sukl.sk/en/servis/search/searching-on-the-database-of-medicinal-products?page_id=410&lie_nazov=&atc_nazov=venlafax%C3%ADn&lie_kod=&atc_kod=&lie_rc=&drz_kod=). Revised January 2020. Accessed January 24, 2020.
  18. Tirona RG, Kim RB. Introduction to Clinical Pharmacology. In: Robertson D, Williams GH. Clinical and Translational Science, 2nd ed. Academic Press; 2017.
  19. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843–53.
  20. Unterecker S, Hiemke C, Greiner C, et al. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry. 2012;45(6):229–35.
  21. World Health Organisation (WHO). Depression and Other Common Mental Disorders. Global Health Estimates. (https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1&isAllowed=y). 2017. Accessed January 24, 2020.
  22. World Health Organisation (WHO). Depression. (https://www.who.int/news-room/fact-sheets/detail/depression). Revised December 2019. Accessed January 23, 2020.
Language: English
Page range: 33 - 37
Submitted on: Feb 28, 2020
Accepted on: Jun 24, 2020
Published on: Nov 18, 2020
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:

© 2020 M. Krivosova, M. Kertys, M. Grendar, I. Ondrejka, I. Hrtanek, I. Tonhajzerova, N. Sekaninova, J. Mokry, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.